Inhibrx Inc (NASDAQ: INBX) — Company Overview, News & Financial Data
Inhibrx is a biotechnology company dedicated to novel therapeutics for cancer and inflammatory conditions, advancing innovative solutions.
Inhibrx Inc
Inhibrx (NASDAQ:INBX), a biotechnology company, is dedicated to the discovery, development, and commercialization of novel therapeutics for the treatment of cancer, infectious diseases, and inflammatory conditions. This commitment is underpinned by its versatile platform and a broad pipeline, including lead programs like INBRX-101 for AATD and INBRX-109 for chondrosarcoma. With a focused approach to leveraging its proprietary technologies, Inhibrx aims to bring innovative solutions to areas of high unmet medical need. The company’s objective centers on advancing these promising therapeutic candidates through clinical trials to ultimately improve patient outcomes across various diseases.
Snapshot
Operations
Products and/or services of Inhibrx Inc
- A therapy targeting CD47 to enable the immune system to combat cancer and other serious diseases more effectively.
- An antibody aimed at treating various solid tumor types through precise targeting of the 4-1BB pathway, enhancing tumor-specific T-cell activity.
- A treatment designed for patients with chondrosarcoma, utilizing a proprietary approach to target and inhibit specific cancer growth pathways.
- A novel therapy focused on addressing the unmet medical needs in patients with pancreatic cancer, employing targeted mechanisms to halt tumor progression.
- Innovative bi-specific antibodies intended to selectively direct the immune system towards cancer cells, minimizing damage to healthy tissues.
- Advanced therapeutic options for the treatment of non-small cell lung cancer, leveraging cutting-edge science to disrupt cancer cell growth and survival.
Inhibrx Inc executive team
- Mark Paul LappeFounder, CEO & Chairman
- David J. MatlyPresident
- Kelly Devine DeckExecutive VP, CFO & Treasurer
- Bonne AdamsVice President of Operations
- Kate BurkeVice President of Accounting
- Ashraf AmanullahExecutive VP & Chief Technical Operations Officer
- Carlos BaisEVP & Chief Scientific Officer
- Leah PollemaVP, General Counsel & Corporate Secretary
- Josep GarciaExecutive VP & Chief Clinical Development Officer
Latest news about Inhibrx Inc
Dividend history
Dividends per share paid by Inhibrx Inc, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2024 | — | — | — | $0.8500 |
Key financials
Reported results for Inhibrx Inc, in USD.
- Market cap
- 1.1B
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -8.9
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 1.3M | -135M | -140.1M | |
| 200K | -331.4M | 1.7B | |
| 1.8M | -219.2M | -241.4M | |
| 2.2M | -129.1M | -145.2M |